ClinicalTrials.gg
BiologicalDrug

Chimeric Antigen Receptor T-cells clinical trials

studies test it
68
open now
42
in phase 3
3
first study started
2016

How each study uses Chimeric Antigen Receptor T-cells is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Chimeric Antigen Receptor T-cells studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

CAR-T cells
19
CAR T cells
12
CAR-T cell
8
CAR-T cells injection
2
CAR T Cell
2

In one entry with another drug

Given together, or one or the other

Chimeric Antigen Receptor T-Cell Therapy
13

Studies by the year they started

68 studies that test it; most in 2025 (13)

Studies that test Chimeric Antigen Receptor T-cells, by start year
YearStudies
20162
20175
20184
20193
20203
20218
20225
20239
202411
202513
20265

Who runs them

Industry 8 · Other 60

City of Hope Medical Center (5) · Zhejiang University (4) · Memorial Sloan Kettering Cancer Center (3) · The Affiliated Hospital of Xuzhou Medical University (3) · Shanghai Changzheng Hospital (2) · Shenzhen Geno-Immune Medical Institute (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · Shenzhen University General Hospital (2)

Often tested with

Tested in the same studies.

Chimeric Antigen Receptor T-Cell Therapy|Chimeric Antigen Receptor T-cell Therapy (14) · Cyclophosphamide (8) · Fludarabine (7) · Odronextamab (3) · Conditioning Chemotherapy (2) · Fludarabine phosphate (2) · Etoposide (2) · Dexamethasone (2)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 14, 1 in phase 3

Studies that test Chimeric Antigen Receptor T-cells, phase 3 first.

Studies

Open first, then newest update. How each study uses Chimeric Antigen Receptor T-cells is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 68

See all 68 studies that test Chimeric Antigen Receptor T-cells →

Given beside what is tested · 7 — Chimeric Antigen Receptor T-cells is usual care or a partner of the new treatment